Globus Medical, Inc.(GMED)Earnings, Financials & Key Ratios

GMED•NYSE

$90.03

$12.18B mkt cap·23.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryOrthopedics, spine, and sports medicine

AboutGlobus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Show more

Revenue$2.94B+16.7%
EBITDA$600M+42.8%
Net Income$538M+422.3%
EPS (Diluted)3.92+422.7%
Gross Margin67.41%+14.4%
EBITDA Margin20.41%+22.4%
Operating Margin16.33%+147.8%
Net Margin18.3%+347.8%
ROE12.29%+388.0%
ROIC8.89%+185.0%
Debt/Equity0.03-79.8%

Analysis→Technical→

GMED Key Insights

Globus Medical, Inc. (GMED) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y profit CAGR of 39.4%
✓Strong Piotroski F-Score: 9/9
✓FCF machine: 20.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 30.1%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

GMED Price & Volume

Globus Medical, Inc. (GMED) stock price & volume — 10-year historical chart

Loading chart...

GMED Growth Metrics

Globus Medical, Inc. (GMED) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years18.36%

5 Years30.08%

3 Years42.16%

TTM16.65%

Profit CAGR

10 Years16.91%

5 Years39.37%

3 Years41.42%

TTM422.31%

EPS CAGR

10 Years12.85%

5 Years31.16%

3 Years28.44%

TTM424.48%

Return on Capital

10 Years11.35%

5 Years8.1%

3 Years6.04%

Last Year10.43%

GMED Recent Earnings

Globus Medical, Inc. (GMED) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 11/12 qtrs (92%)

Q1 2026Latest

Feb 24, 2026

EPS

$1.28

Est $1.06

+20.8%

Revenue

$826M

Est $802M

+3.1%

Q4 2025

Nov 6, 2025

EPS

$1.18

Est $0.78

+51.1%

Revenue

$769M

Est $735M

+4.7%

Q3 2025

Aug 7, 2025

EPS

$0.86

Est $0.76

+13.2%

Revenue

$745M

Est $743M

+0.4%

Q2 2025

May 8, 2025

EPS

$0.68

Est $0.74

-8.6%

Revenue

$598M

Est $626M

-4.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 24, 2026	$1.28vs $1.06+20.8%	$826Mvs $802M+3.1%
Q4 2025	Nov 6, 2025	$1.18vs $0.78+51.1%	$769Mvs $735M+4.7%
Q3 2025	Aug 7, 2025	$0.86vs $0.76+13.2%	$745Mvs $743M+0.4%
Q2 2025	May 8, 2025	$0.68vs $0.74-8.6%	$598Mvs $626M-4.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
SYKStryker CorporationDirect Competitor	113.08B	295.25	35.15	11.16%	12.92%	15.04%	3.79%	0.66
ZBHZimmer Biomet Holdings, Inc.Direct Competitor	16.25B	83.01	23.38	7.2%	9.05%	5.77%	9.06%	0.59
ATECAlphatec Holdings, Inc.Direct Competitor	1.55B	10.23	-10.66	24.95%	-21.07%	-141.88%	0.18%	17.21
XTNTXtant Medical Holdings, Inc.Direct Competitor	81.2M	0.58	-4.83	28.44%	1.32%	3.77%		0.82
MDTMedtronic plcProduct Competitor	99.73B	77.79	21.55	3.62%	13%	9.45%	5.2%	0.59
BSXBoston Scientific CorporationProduct Competitor	83.2B	55.98	28.86	19.87%	14.4%	12.4%	4.4%	0.51
HOLXHologic, Inc.Product Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	5.42%	0.52
NVCRNovoCure LimitedProduct Competitor	1.81B	15.88	-13.02	8.28%	-25.66%	-50.82%		0.85

Compare GMED vs Peers

Globus Medical, Inc. (GMED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SYK

Most directly comparable listed peer for GMED.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare GMED against a more recognizable public peer.

Peer Set

Compare Top 5

vs SYK, ZBH, ATEC, XTNT

GMED Income Statement

Globus Medical, Inc. (GMED) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	635.98M	712.97M	785.37M	789.04M	958.1M	1.02B	1.57B	2.52B	2.94B
Revenue Growth %	12.76%	12.11%	10.15%	0.47%	21.43%	6.76%	53.34%	60.62%	16.65%
Cost of Goods Sold	150.45M	159.41M	179.97M	217.46M	239.22M	263.73M	548.17M	1.04B	957.8M
COGS % of Revenue	23.66%	22.36%	22.92%	27.56%	24.97%	25.78%	34.95%	41.1%	32.59%
Gross Profit	485.52M▲ 0%	553.56M▲ 14.0%	605.39M▲ 9.4%	571.58M▼ 5.6%	718.88M▲ 25.8%	759.12M▲ 5.6%	1.02B▲ 34.4%	1.48B▲ 45.4%	1.98B▲ 33.5%
Gross Margin %	76.34%	77.64%	77.08%	72.44%	75.03%	74.22%	65.05%	58.9%	67.41%
Gross Profit Growth %	13.1%	14.01%	9.36%	-5.59%	25.77%	5.6%	34.41%	45.43%	33.51%
Operating Expenses	323.68M	384.23M	433.4M	460.15M	546.93M	531.17M	887.16M	1.32B	1.5B
OpEx % of Revenue	50.9%	53.89%	55.18%	58.32%	57.08%	51.93%	56.56%	52.31%	51.08%
Selling, General & Admin	267.82M	311.59M	354.76M	354.76M	408.15M	432.12M	643.41M	981.05M	1.32B
SG&A % of Revenue	42.11%	43.7%	45.17%	44.96%	42.6%	42.25%	41.02%	38.94%	44.79%
Research & Development	43.68M	55.5M	60.07M	84.52M	97.35M	73.02M	124.01M	163.75M	185M
R&D % of Revenue	6.87%	7.78%	7.65%	10.71%	10.16%	7.14%	7.91%	6.5%	6.29%
Other Operating Expenses	12.19M	17.15M	18.57M	20.87M	41.43M	26.04M	119.74M	173.08M	0
Operating Income	161.84M▲ 0%	169.32M▲ 4.6%	171.99M▲ 1.6%	111.43M▼ 35.2%	171.95M▲ 54.3%	227.95M▲ 32.6%	133.14M▼ 41.6%	165.99M▲ 24.7%	479.8M▲ 189.1%
Operating Margin %	25.45%	23.75%	21.9%	14.12%	17.95%	22.29%	8.49%	6.59%	16.33%
Operating Income Growth %	4.99%	4.62%	1.57%	-35.21%	54.31%	32.57%	-41.59%	24.67%	189.05%
EBITDA	203.91M	210.96M	224.72M	174.31M	241.82M	296.2M	277.88M	420.01M	599.8M
EBITDA Margin %	32.06%	29.59%	28.61%	22.09%	25.24%	28.96%	17.72%	16.67%	20.41%
EBITDA Growth %	5.7%	3.46%	6.53%	-22.43%	38.73%	22.49%	-6.19%	51.15%	42.8%
D&A (Non-Cash Add-back)	42.07M	41.63M	52.73M	62.87M	69.87M	68.25M	144.73M	254.02M	120M
EBIT	163.32M	176.88M	176.75M	115.47M	194.86M	236.25M	201.85M	219.7M	609.9M
Net Interest Income	6.61M	13.28M	17.41M	13.95M	9.3M	14.23M	20.13M	-4.19M	7.14M
Interest Income	6.61M	13.28M	17.41M	13.95M	9.3M	14.23M	20.13M	0	7.14M
Interest Expense	0	0	0	0	0	0	0	4.19M	0
Other Income/Expense	8.09M	19.28M	17.96M	14.47M	8.45M	15.07M	32.25M	-45.27M	130.1M
Pretax Income	169.93M▲ 0%	188.6M▲ 11.0%	189.95M▲ 0.7%	125.9M▼ 33.7%	180.41M▲ 43.3%	243.02M▲ 34.7%	165.39M▼ 31.9%	120.72M▼ 27.0%	609.9M▲ 405.2%
Pretax Margin %	26.72%	26.45%	24.19%	15.96%	18.83%	23.76%	10.54%	4.79%	20.75%
Income Tax	62.58M	32.13M	34.74M	23.61M	31.22M	52.85M	42.52M	17.74M	72M
Effective Tax Rate %	36.83%	17.04%	18.29%	18.76%	17.3%	21.75%	25.71%	14.69%	11.81%
Net Income	107.35M▲ 0%	156.47M▲ 45.8%	155.21M▼ 0.8%	102.28M▼ 34.1%	149.19M▲ 45.9%	190.17M▲ 27.5%	122.87M▼ 35.4%	102.98M▼ 16.2%	537.9M▲ 422.3%
Net Margin %	16.88%	21.95%	19.76%	12.96%	15.57%	18.59%	7.83%	4.09%	18.3%
Net Income Growth %	2.88%	45.76%	-0.81%	-34.1%	45.86%	27.47%	-35.39%	-16.19%	422.31%
Net Income (Continuing)	107.35M	156.47M	155.21M	102.28M	149.19M	190.17M	122.87M	102.98M	537.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	1.10▲ 0%	1.54▲ 40.0%	1.52▼ 1.3%	1.01▼ 33.6%	1.44▲ 42.6%	1.85▲ 28.5%	1.07▼ 42.2%	0.75▼ 29.9%	3.92▲ 422.7%
EPS Growth %	1.85%	40%	-1.3%	-33.55%	42.57%	28.47%	-42.16%	-29.91%	422.67%
EPS (Basic)	1.12	1.60	1.57	1.04	1.48	1.89	1.09	0.76	3.98
Diluted Shares Outstanding	97.89M	101.32M	102M	100.97M	103.62M	102.64M	114.63M	137.86M	137.22M
Basic Shares Outstanding	96.24M	97.88M	99.15M	98.58M	100.73M	100.47M	113.09M	135.73M	135.15M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

GMED Balance Sheet

Globus Medical, Inc. (GMED) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	620.34M	630.68M	687.47M	821.76M	864.52M	983.34M	1.92B	2.18B	2.13B
Cash & Short-Term Investments	373.71M	339.68M	311.49M	426.74M	443.45M	446.06M	517.79M	890.06M	557.24M
Cash Only	118.82M	139.75M	195.72M	239.4M	193.07M	150.47M	467.29M	784.44M	526.16M
Short-Term Investments	254.89M	199.94M	115.76M	187.34M	250.38M	295.59M	50.5M	105.62M	31.09M
Accounts Receivable	127.06M	144.36M	162.42M	148.1M	165.65M	217.31M	504.87M	578.33M	678.94M
Days Sales Outstanding	72.92	73.9	75.49	68.51	63.11	77.55	117.49	83.79	84.32
Inventory	108.41M	131.25M	196.31M	229.15M	237M	298.98M	848.13M	659.23M	759.28M
Days Inventory Outstanding	263	300.53	398.14	384.62	361.61	413.79	564.73	232.38	289.35
Other Current Assets	0	100K	0	0	0	21M	44.58M	49.64M	130.15M
Total Non-Current Assets	458.16M	669.99M	844.61M	857.72M	1.09B	1.09B	3.17B	3.07B	3.18B
Property, Plant & Equipment	143.17M	171.87M	199.84M	216.88M	221.08M	243.73M	646.86M	611.56M	628.24M
Fixed Asset Turnover	4.44x	4.15x	3.93x	3.64x	4.33x	4.20x	2.42x	4.12x	4.68x
Goodwill	123.89M	123.73M	128.78M	156.72M	179.71M	197.47M	1.43B	1.43B	1.44B
Intangible Assets	78.66M	87.32M	78.81M	86.95M	68.66M	63.57M	924.6M	795.12M	745.06M
Long-Term Investments	56.13M	263.12M	409.51M	358.52M	562.48M	495.85M	75.43M	66.13M	0
Other Non-Current Assets	36.28M	10.36M	21.74M	32.04M	36.33M	43.31M	78.59M	75.1M	150.6M
Total Assets	1.08B▲ 0%	1.3B▲ 20.6%	1.53B▲ 17.8%	1.68B▲ 9.6%	1.96B▲ 16.5%	2.08B▲ 6.1%	5.09B▲ 145.0%	5.25B▲ 3.3%	5.3B▲ 1.0%
Asset Turnover	0.59x	0.55x	0.51x	0.47x	0.49x	0.49x	0.31x	0.48x	0.55x
Asset Growth %	16.26%	20.6%	17.79%	9.62%	16.54%	6.07%	144.98%	3.26%	0.97%
Total Current Liabilities	93.07M	96.12M	111.4M	120.79M	140.16M	159.2M	392.35M	855.91M	498.5M
Accounts Payable	25.04M	25.89M	24.61M	18.2M	21.95M	36.1M	56.67M	75.12M	98.85M
Days Payables Outstanding	60.74	59.29	49.92	30.56	33.5	49.96	37.73	26.48	37.67
Short-Term Debt	0	0	0	0	0	0	0	443.35M	14.74M
Deferred Revenue (Current)	755K	2.6M	5.4M	8.13M	12.03M	14.1M	18.37M	22.14M	27.66M
Other Current Liabilities	40.42M	39.3M	43.91M	50.73M	64.18M	66.66M	201.85M	185.56M	357.25M
Current Ratio	6.67x	6.56x	6.17x	6.80x	6.17x	6.18x	4.88x	2.54x	4.26x
Quick Ratio	5.50x	5.20x	4.41x	4.91x	4.48x	4.30x	2.72x	1.77x	2.74x
Cash Conversion Cycle	275.18	315.14	423.7	422.57	391.22	441.38	644.48	289.68	336
Total Non-Current Liabilities	17.65M	19.04M	18.22M	52.4M	75.71M	70.55M	695.78M	218.5M	231.01M
Long-Term Debt	0	0	0	0	0	0	417.4M	0	103.92M
Capital Lease Obligations	0	0	0	0	0	3.48M	91.04M	83.59M	0
Deferred Tax Liabilities	10.67M	8.11M	6.02M	6.2M	4.31M	1.78M	84.42M	23.89M	23.76M
Other Non-Current Liabilities	6.98M	10.92M	12.2M	46.19M	71.4M	65.3M	102.92M	111.03M	103.34M
Total Liabilities	110.72M	115.15M	129.63M	173.19M	215.88M	229.75M	1.09B	1.07B	729.51M
Total Debt	0	0	0	0	0	6.01M	520.4M	537.19M	118.66M
Net Debt	-118.82M	-139.65M	-195.72M	-239.4M	-193.07M	-144.46M	53.11M	-247.25M	-407.5M
Debt / Equity	-	-	-	-	-	0.00x	0.13x	0.13x	0.03x
Debt / EBITDA	-	-	-	-	-	0.02x	1.87x	1.28x	0.20x
Net Debt / EBITDA	-0.58x	-0.66x	-0.87x	-1.37x	-0.80x	-0.49x	0.19x	-0.59x	-0.68x
Interest Coverage	-	-	-	-	-	-	-	52.45x	-
Total Equity	967.78M▲ 0%	1.19B▲ 22.5%	1.4B▲ 18.3%	1.51B▲ 7.4%	1.74B▲ 15.6%	1.85B▲ 6.0%	4B▲ 116.5%	4.18B▲ 4.5%	4.57B▲ 9.5%
Equity Growth %	16.31%	22.5%	18.3%	7.4%	15.61%	6.03%	116.53%	4.49%	9.48%
Book Value per Share	9.89	11.70	13.75	14.92	16.81	17.99	34.88	30.30	33.33
Total Shareholders' Equity	967.78M	1.19B	1.4B	1.51B	1.74B	1.85B	4B	4.18B	4.57B
Common Stock	97K	98K	99K	99K	101K	100K	136K	137K	135K
Retained Earnings	736.25M	892.72M	1.05B	1.05B	1.19B	1.24B	1.14B	1.15B	1.39B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6.91M	-7.17M	-2.9M	3.96M	-6.77M	-24.63M	-10.19M	-6.86M	15.35M
Minority Interest	0	0	0	0	0	0	0	0	0

GMED Cash Flow Statement

Globus Medical, Inc. (GMED) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	159.53M	181.64M	171.97M	198.79M	276.27M	178.47M	243.5M	520.64M	753.45M
Operating CF Margin %	25.09%	25.48%	21.9%	25.19%	28.84%	17.45%	15.52%	20.67%	25.64%
Operating CF Growth %	-7.19%	13.86%	-5.32%	15.59%	38.98%	-35.4%	36.44%	113.82%	44.72%
Net Income	107.35M	156.47M	155.21M	102.28M	149.19M	190.17M	122.87M	102.98M	537.87M
Depreciation & Amortization	42.07M	41.63M	52.73M	62.87M	69.87M	68.25M	144.73M	254.02M	276.84M
Stock-Based Compensation	14.69M	21.9M	26.09M	27.07M	30.59M	32.81M	52.74M	54.19M	49.78M
Deferred Taxes	8.29M	971K	4.3M	-4.34M	-17.61M	-22.22M	-57.79M	-125.9M	18.63M
Other Non-Cash Items	17.66M	10.54M	7.09M	48.49M	61.5M	14.72M	97.54M	332.89M	-46.95M
Working Capital Changes	-30.52M	-49.87M	-73.44M	-37.59M	-17.25M	-105.26M	-116.6M	-97.55M	-82.71M
Change in Receivables	-24.95M	-21.79M	-18.31M	10.7M	-25.89M	-50.84M	-49.91M	-78.06M	-52.18M
Change in Inventory	-5.28M	-31.38M	-50.02M	-50.11M	-11.97M	-61.74M	-70.33M	-29.86M	-17.6M
Change in Payables	9.84M	-3.01M	773K	-6.35M	3.68M	14.42M	-14.22M	17.66M	8.49M
Cash from Investing	-111.28M	-193.03M	-140.28M	-117.32M	-375.94M	-110.36M	302.97M	-176.05M	-355.01M
Capital Expenditures	-51.3M	-59.7M	-70.75M	-63.66M	-56.9M	-74.05M	-78.27M	-115.43M	-164.68M
CapEx % of Revenue	8.07%	8.37%	9.01%	8.07%	5.94%	7.24%	4.99%	4.58%	5.6%
Acquisitions	-29.94M	-14.82M	-23.8M	-33.48M	-34.49M	-31.43M	-296.03M	-17.64M	13.46M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	35M	0	0	0	0	0	0	-275.75M
Cash from Financing	1.63M	32.57M	24.44M	-38.66M	54.15M	-109.96M	-231.82M	-27.7M	-679.16M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	11.73M	39.31M	31.04M	-104.67M	0	-144.49M	-225.56M	-85.79M	-300.45M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	-104.67M	0	-144.49M	-225.56M	-85.79M	-300.45M
Other Financing	-10.11M	-6.74M	-6.6M	66.01M	54.15M	34.53M	-6.26M	58.09M	-378.71M
Net Change in Cash	51.86M▲ 0%	20.93M▼ 59.6%	55.98M▲ 167.4%	43.67M▼ 22.0%	-46.33M▼ 206.1%	-42.6M▲ 8.0%	316.83M▲ 843.7%	317.15M▲ 0.1%	-258.28M▼ 181.4%
Free Cash Flow	108.23M▲ 0%	121.95M▲ 12.7%	101.22M▼ 17.0%	135.13M▲ 33.5%	219.38M▲ 62.3%	104.42M▼ 52.4%	165.22M▲ 58.2%	405.21M▲ 145.2%	588.77M▲ 45.3%
FCF Margin %	17.02%	17.1%	12.89%	17.13%	22.9%	10.21%	10.53%	16.08%	20.03%
FCF Growth %	-17.37%	12.67%	-16.99%	33.5%	62.34%	-52.4%	58.23%	145.25%	45.3%
FCF per Share	1.11	1.20	0.99	1.34	2.12	1.02	1.44	2.94	4.29
FCF Conversion (FCF/Net Income)	1.49x	1.16x	1.11x	1.94x	1.85x	0.94x	1.98x	5.06x	1.40x
Interest Paid	3K	6K	79K	0	0	0	0	0	0
Taxes Paid	59.11M	30.55M	34.14M	25.44M	45.03M	77.82M	100.59M	158.51M	0

GMED Key Ratios

Globus Medical, Inc. (GMED) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	13.49%	11.93%	14.53%	11.99%	7.03%	9.19%	10.6%	4.2%	2.52%	12.29%
Return on Invested Capital (ROIC)	16.28%	15.04%	13.4%	11.45%	6.76%	9.16%	10.52%	3.47%	3.12%	8.89%
Gross Margin	76.12%	76.34%	77.64%	77.08%	72.44%	75.03%	74.22%	65.05%	58.9%	67.41%
Net Margin	18.5%	16.88%	21.95%	19.76%	12.96%	15.57%	18.59%	7.83%	4.09%	18.3%
Debt / Equity	-	-	-	-	-	-	0.00x	0.13x	0.13x	0.03x
Interest Coverage	-	-	-	-	-	-	-	-	52.45x	-
FCF Conversion	1.65x	1.49x	1.16x	1.11x	1.94x	1.85x	0.94x	1.98x	5.06x	1.40x
Revenue Growth	3.53%	12.76%	12.11%	10.15%	0.47%	21.43%	6.76%	53.34%	60.62%	16.65%

GMED SEC Filings & Documents

Globus Medical, Inc. (GMED) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 23, 2026·SEC

Material company update

Feb 24, 2026·SEC

Material company update

Jan 7, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 20, 2025·SEC

FY 2024

Feb 21, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

GMED Frequently Asked Questions

Globus Medical, Inc. (GMED) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Globus Medical, Inc. (GMED) reported $2.94B in revenue for fiscal year 2025. This represents a 920% increase from $288.2M in 2010.

Globus Medical, Inc. (GMED) grew revenue by 16.7% over the past year. This is strong growth.

Yes, Globus Medical, Inc. (GMED) is profitable, generating $537.9M in net income for fiscal year 2025 (18.3% net margin).

Dividend & Returns

Globus Medical, Inc. (GMED) has a return on equity (ROE) of 12.3%. This is reasonable for most industries.

Globus Medical, Inc. (GMED) generated $578.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More GMED

Globus Medical, Inc. (GMED) financial analysis — history, returns, DCA and operating performance tools

Full GMED Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Globus Medical, Inc.(GMED)Earnings, Financials & Key Ratios

GMED Key Insights

✓Strengths

✗Weaknesses

GMED Price & Volume

GMED Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

GMED Recent Earnings

GMED Peer Comparison

Compare GMED vs Peers

vs SYK

vs ISRG

Compare Top 5

GMED Income Statement

GMED Balance Sheet

GMED Cash Flow Statement

GMED Key Ratios

GMED SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

GMED Frequently Asked Questions

Explore More GMED

Full GMED Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation